AP
SCLN

Advisors Preferred’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Advisors Preferred’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-1,100
Closed -$12K – 292
2016
Q4 		$12K Buy
+1,100
New +$11K 0.01% 178
2016
Q3 		– Sell
-3,132
Closed -$41K – 296
2016
Q2 		$41K Buy
+3,132
New +$41K 0.02% 103

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Advisors Preferred's SCLN Position: Q1 2017 in Review

Advisors Preferred sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q1 2017, closing a stake of 1,100 shares — an estimated $12K sold.

Advisors Preferred first reported a position in SCLN in Q2 2016 and held it in 2 quarters. The position peaked at $41K in Q2 2016. 136 funds tracked by Wall St. Rank hold SCLN as of Q1 2017.

  • Advisors Preferred reported no remaining Sciclone Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Advisors Preferred sold 1,100 Sciclone Pharmaceuticals Inc shares in Q1 2017, an estimated $12K.
  • Advisors Preferred first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 2 quarters.
  • Advisors Preferred's Sciclone Pharmaceuticals Inc position peaked at $41K in Q2 2016.
  • 136 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q1 2017.

Based on Advisors Preferred's 13F filing for Q1 2017, filed 3 May 2017.